Over-encapsulation involves placing a product or solid oral dosage forms (e.g., tablets, caplets, capsules) into an opaque empty hard gelatin or HPMC capsule. This process prevents investigators and subjects from identifying which capsules contain the active medication and which contain the placebo or comparator product. Over-encapsulation is one of the most effective ways to blind both approved and investigational drugs, ensuring unbiased testing during clinical trials.
What are Clinical Capsules or Clinical Trial Capsules?
Clinical capsules are specialty capsules designed for use in pre-clinical and clinical studies. These capsules are typically empty hard gelatin (two-piece gelatin) or hydroxypropyl methylcellulose (HPMC) capsules that have undergone over-encapsulation or other forms of masking to distinguish them from other dosage forms, such as placebo drugs. This masking helps improve the cost efficiency of trials by reducing the need to produce placebo forms identical in size and shape to the candidate drug.
Clinical trial supplies refer to the distribution of drug products that are packaged, labeled, and manufactured in compliance with current Good Manufacturing Practice (cGMP) guidelines for clinical trials. These small batches of prepackaged clinical trial supplies are used for clinical research of drug products through pre-clinical trials and human testing. Before commercial manufacturing at a production scale, clinical trial material manufacturing services are carried out during earlier phases of clinical development.
Types of Clinical Trial Capsules Based on Capsule Shell Ingredients
- Hard Gelatin Capsules:
- Hard gelatin capsules are solid oral dosage forms where one or more medicinal agents and/or inert materials are enclosed within a hard capsule shell made of gelatin. These capsules are available only in cylindrical, two-piece forms and contain a lower ratio of plasticizer to gelatin compared to soft gelatin capsules. They may also include materials such as plasticizers, colorants, water, opacifying agents, and preservatives to enhance their performance and bioavailability.
- Hydroxypropyl Methylcellulose (HPMC) Capsules:
- HPMC capsules, also known as vegetarian capsules, are made from cellulose and are an alternative to gelatin capsules. These capsules can be filled with active pharmaceutical ingredients in powder, liquid, or semi-solid forms. HPMC capsules are attractive, natural solid oral dosage forms that are easy to swallow, effectively mask taste and odor, and allow product visibility. They offer advantages such as low moisture content and the ability to delay drug release, making them suitable for supplements and other applications.
Over-Encapsulation
Over-encapsulation involves placing a product or solid oral dosage forms (e.g., tablets, caplets, capsules) into an opaque empty hard gelatin or HPMC capsule. This process prevents investigators and subjects from identifying which capsules contain the active medication and which contain the placebo or comparator product. Over-encapsulation is one of the most effective ways to blind both approved and investigational drugs, ensuring unbiased testing during clinical trials.
Benefits of Over-Encapsulation:
- Multiple doses can look the same in appearance.
- Applicable to solid oral dosage forms such as tablets and capsules.
- Minor manufacturing developments.
- Matching placebo is easily manufactured using a common capsule shell with common backfill.
What are Double-Blind Capsules? How are They Useful for Clinical Trials?
Clinical trial materials (CTM) are licensed finished dosage forms or drug products produced in small batches suitable for human dosing tests but not intended for commercial manufacturing.
A blinded (or masked) clinical trial is a study in which the recipient does not know if they are receiving the actual drug or a placebo. In a double-blind clinical trial, neither the recipient nor the administrator knows if the recipient is receiving the actual drug. This approach helps provide a more complete understanding of a drug’s effectiveness, benefits, and potential adverse reactions without the bias of the “placebo effect” or experimenter bias.
Double-blinding involves defining the pharmaceutical form and choosing the labeling according to the study design. The requirement for matching extends to all associated packaging and labeling.
Blinding Methods
- Over-encapsulation
- Milling and filling of capsules
- Removing markings
- Manufacturing a generic product
- Producing similar-looking products
- Overcoating
While various methods can be used to blind dosage forms in CTMs, over-encapsulation is the most common process for producing double-blind capsules for trials. Over-encapsulation involves placing the product (e.g., tablets, caplets, capsules) into an opaque capsule shell to conceal the contents, making the products visually identical. Alternatively, blinding two substantially different-looking treatments can be achieved by manufacturing both treatments into either capsules or tablets.
Benefits of Double-Blind Capsules
- Prevention of Bias: Double-blind capsules prevent bias due to demand characteristics or the placebo effect.
- Minimized Risk of Bias: The drug’s effect is not influenced by its recognizable features (e.g., color, shape, smell, or taste) or by the investigator’s behavior, minimizing the risk of false positive or false negative bias in clinical study results.
- Improved Patient Compliance: Active comparator products can be discreetly enclosed, and the tamper-evident design prevents bias.
- Ease of Use: Double-blind capsules are easy to swallow, leading to better patient compliance.
What are the Techniques to Overcome the Challenges of Blinding Clinical Trial Materials?
The design of a clinical study, the characteristics of the comparator drug product, and the advantages and challenges of each blinding option must be considered to determine the best method for blinding dosage forms for clinical trials.
Over-encapsulation has become the most widely used technique for blinding CTMs. This method offers clinical supply solutions by blinding supplies in clinical studies, which are larger, more complex, and spread across more countries than ever before. Over-encapsulated double-blind capsules help overcome blinding challenges, allowing the administration of a study drug without participants and investigators knowing whether they are receiving or administering the investigational product or placebo.
Challenges of Over-Encapsulation
- Effect on Dissolution, Disintegration, and Bioequivalence: Over-encapsulation can affect the absorption, solubility, and bioavailability of drug products.
- Interactions Between Backfill and Gelatin Capsules: The choice of backfill may affect the dissolution profile.
- Labor Intensity: The process can be labor-intensive.
- Breaking of Blind: There is a risk of breaking the blind.
- Size Accommodation: Accommodating the size of the over-encapsulated product can be challenging.
The dissolution profile of an over-encapsulated product depends on the properties of the active pharmaceutical ingredient (API), the characteristics of the over-encapsulated unit, and the backfill. While blinding the drug product or placebo in a capsule might not affect dissolution, the choice of backfill may.
According to GMP regulations for CTM manufacturing, study sponsors must provide data (e.g., about dissolution, disintegration, and bioequivalence) demonstrating that over-encapsulation will not alter product quality. The use of backfill requires additional compatibility and preformulation studies.
It is recommended to perform extensive preliminary tests before manufacturing clinical trial capsules for clinical and commercial supply. By understanding and controlling every step of over-encapsulation—from material selection to manufacture—one can ensure the integrity of the study and avoid bias and other challenges of blinding clinical trial materials.
Related Services
FAQs
Here are some frequently asked questions about Semi-Solids & Gels
Semi-solid dosage forms include creams, ointments, gels, and pastes, designed for external application to the skin or mucous membranes. They are characterized by their thick consistency, which allows them to adhere to the application site for effective drug delivery. These dosage forms are used to treat a wide range of conditions, from skin diseases to localized pain relief.
Semi-solid dosage forms offer several benefits, including targeted drug delivery to specific areas, reduced systemic side effects, and enhanced patient compliance due to ease of application. They can provide both local and systemic effects, depending on the formulation, and are particularly useful for delivering drugs that are not suitable for oral administration due to stability or bioavailability issues.
The formulation of semi-solid dosage forms involves the selection of appropriate base materials (such as hydrocarbons for ointments, water or alcohol for gels, and various emulsifiers for creams) that determine the product's texture, stability, and drug release characteristics. Active pharmaceutical ingredients (APIs) are then incorporated into the base, along with other excipients like preservatives, antioxidants, and skin conditioners, to achieve the desired therapeutic effect and product stability.
Stability considerations for semi-solid dosage forms include maintaining the consistency, efficacy, and integrity of the product throughout its shelf life. This involves ensuring the physical stability (to prevent separation or crystallization of components), chemical stability (to prevent degradation of active ingredients), and microbiological stability (to prevent contamination). Stability testing under various conditions is critical to determining the product's expiration date.
Ensuring uniformity of dosage in semi-solid forms involves rigorous manufacturing processes and quality control measures. The manufacturing process must ensure thorough mixing and homogenization of the API throughout the base. Quality control tests, including content uniformity and viscosity measurements, are conducted on each batch to ensure that the final product meets the specified criteria for uniformity and consistency.
Yes, semi-solid dosage forms can be designed for controlled release of the active ingredient. This is achieved through the use of specific formulation strategies and excipients that modify the drug release profile, such as polymers that form a matrix with the drug or encapsulation techniques that slow the diffusion of the drug from the base. Controlled release formulations can enhance therapeutic efficacy and improve patient compliance by reducing the frequency of application.
Packaging options for semi-solid dosage forms include tubes, jars, pump dispensers, and single-use sachets. The choice of packaging is based on the product's viscosity, intended use, and stability requirements. Packaging materials must protect the product from contamination, light, and air, and be compatible with the formulation to prevent interaction with the packaging.
Quality assurance testing for semi-solid dosage forms includes physical, chemical, and microbiological tests. Physical tests evaluate the product's appearance, pH, viscosity, and spreadability. Chemical tests assess the potency and purity of the active ingredients and the presence of degradation products. Microbiological tests ensure the product is free from harmful microorganisms. All tests are conducted in accordance with regulatory guidelines to ensure product safety and efficacy.
c
Regulatory considerations for semi-solid dosage forms involve compliance with guidelines provided by regulatory agencies such as the FDA, EMA, and others. These guidelines cover the formulation, manufacturing process, quality control, packaging, labeling, and stability testing. The submission of a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) is required for market approval, including detailed documentation of the product's formulation, manufacturing process, and validation of analytical methods.
Renejix Pharma Solutions offers comprehensive services for the development and manufacturing of semi-solid dosage forms, including formulation development, process optimization, scale-up, manufacturing, and packaging. Renejix can provide expertise in selecting appropriate base materials, excipients, and manufacturing processes to meet the product's specifications and regulatory requirements. Additionally, Renejix can assist with stability studies, quality assurance testing, and regulatory submission, facilitating a smooth path from concept to commercialization.